Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
Filings by filing date
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 6320 Canoga Avenue, 15Th Floor WOODLAND HILLS CA 91367 |
Tel: | 1-800-7011223 |
Website: | https://endonovo.com |
IR: | See website |
Key People | ||
Ira Weisberg President, Chief Commercial Officer - Medical Division | Alan Brian Collier Chief Executive Officer, Interim Chief Financial Officer, Secretary, Director | Nevena Zubcevik Chief Medical Officer |
Business Overview |
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems. |
Financial Overview |
For the nine months ended 30 September 2023, Endonovo Therapeutics Inc revenues increased from $14K to $134K. Net income totaled $8.5M vs. loss of $5.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Change in fair value of derivative liab. increase from $1.9M (expense) to $11.4M (income), Operating Expenses decrease of 19% to $2.3M (expense). |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $8.05M as of Sep 30, 2023 |
Annual revenue (TTM): | $0.26M as of Sep 30, 2023 |
EBITDA (TTM): | -$1.97M as of Sep 30, 2023 |
Net annual income (TTM): | -$4.40M as of Sep 30, 2023 |
Free cash flow (TTM): | -$0.63M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | $7.06M as of Sep 30, 2023 |
Shares outstanding: | 318,751,597 as of Dec 28, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |